Evotec SE (EVO:NASDAQ) closed at $1.58 on November 13, 2026, down 4.82% on the day. The stock trades 59.2% below its 52-week high of $3.87 and 18.8% above its 52-week low of $1.33. Over the past year, it lost 46.6%. Evotec SE is part of the Health Care sector.
In 252 trading sessions since November 13, 2025, EVO closed higher on 112 days (44%). Its best day was November 5, 2026 (+13.38%) and its worst was July 13, 2026 (-12.90%). The stock moved 10% or more in a single session 7 times. It opened at least 5% above the previous day's high 5 times.
Evotec SE is a drug discovery partnership company providing solutions to pharmaceutical & biotechnology companies, academic institutions as well as foundations, and not-for-profit organizations. The company offers its services in the area of neuronal diseases, diabetes & its complications, pain, inflammation, oncology, infectious diseases, respiratory & fibrosis, rare disease, and women's health. Its business segments are EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone drug discovery services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The majority of its revenue is derived from the EVT Execute segment.
Find more stocks like EVO with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.